1254347-07-3

Basic information

• Product Name: phenyl 4-bromo-6-hydroxy-3-methoxy-2-methylbenzoate
• Synonyms: phenyl 4-bromo-6-hydroxy-3-methoxy-2-methylbenzoate
• CAS NO: 1254347-07-3
• Molecular Weight: 337.17
• Mol File: 1254347-07-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: phenyl 4-bromo-6-hydroxy-3-methoxy-2-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: phenyl 4-bromo-6-hydroxy-3-methoxy-2-methylbenzoate(1254347-07-3)
• EPA Substance Registry System: phenyl 4-bromo-6-hydroxy-3-methoxy-2-methylbenzoate(1254347-07-3)

Safety Data

• Hazardous Substances Data: 1254347-07-3(Hazardous Substances Data)

Upstream product

• 108-95-2 phenol 
• 1175095-38-1 6-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 
• 490-79-9 2,5-dihydroxybenzoic acid. 
• 35458-39-0 4-bromo-2,5-dimethoxybenzoic acid 
• 2674-34-2 1,4-dibromo-2,5-dimethoxybenzene 
• 150-78-7 1,4-dimethoxybezene 
• 50868-73-0 2-methoxy-6-methylbenzeneamine 
• 1254340-85-6 phenyl 4-bromo-2-methoxy-6-methylbenzoate 
• 1244949-43-6 4-bromo-2-methoxy-6-methyl-benzaldehyde 
• 877149-08-1 4-bromo-2-methoxy-6-methyl-benzoic acid 
• 877149-05-8 4-bromo-2-methoxy-6-methyl-benzonitrile 
• 348169-39-1 4-bromo-2-methoxy-6-methyl-phenylamine 

Downstream Products

• 1254347-08-4 phenyl 4-bromo-6-{[(tert-butoxy)carbonyl]oxy}-3-methoxy-2-methylbenzoate 
• 1335556-22-3 phenyl 4-(benzyloxy)-7-methoxy-6-methyl-2-tert-pentylisoindoline-5-carboxylate 
• 1335557-44-2 C₁₆H₁₃BrO₅ 
• 1335557-45-3 C₂₃H₂₁BrO₅ 
• 1335557-46-4 C₂₄H₂₄O₆ 
• 1335557-47-5 C₂₄H₂₂Cl₂O₄ 
• 1254351-84-2 C₂₂H₁₉BrO₄ 

Relevant articles and documents

Process Development and Scale-up of Fully Synthetic Tetracycline TP-2758: A Potent Antibacterial Agent with Excellent Oral Bioavailability

Process research and development of the fully synthetic broad spectrum tetracycline TP-2758, with a chiral pyrrolidine side chain at the C-8 position, is described. The process utilizes two key intermediates, 7 and 10, in a convergent approach that allows for manufacturing of sufficient quantities of API to supply preclinical and early clinical development. The pyrrolidine moiety was introduced into the left-hand piece (LHP) 10 with high enantioselectivity using Ellman's sulfinamide chemistry, and the absolute configuration was confirmed by X-ray crystal structure analysis.

Synthesis and biological evaluation of 8-aminomethyltetracycline derivatives as novel antibacterial agents

The C-8 position of the tetracyclines has been largely underexplored because of limitations in traditional semisynthetic techniques. Employing a total synthetic approach allowed for modifications at the C-7 and C-8 positions, enabling the generation of structure-activity relationships for overcoming the two most common tetracycline bacterial-resistance mechanisms: ribosomal protection (tet(M)) and efflux (tet(A)). Ultimately, several compounds were identified with balanced activity against both Gram-positive and Gram-negative bacteria, including pathogens bearing both types of tetracycline-resistance mechanisms. Compounds were screened in a murine systemic infection model to rapidly identify compounds with oral bioavailability, leading to the discovery of several compounds that exhibited efficacy when administered orally in murine pyelonephritis and pneumonia models.

POLYCYCLIC TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.